2026-02-13 02:35Company and Industry Summary Company: WuXi AppTec (药明康德) Key Points - Revenue Growth: WuXi AppTec has announced a revenue forecast for 2025 of 45.46 billion yuan, representing a year-on-year increase of 15.8%. The revenue from continuing operations is expected to grow at a rate of 21.4% [1] - Guidance vs. Actuals: The company's guidance for 2025 was between 43.5 billion and 44 billion yuan, with a growth rate for continuing operations projected at 17-18%. The actual forecast exceeds this guidance, indicating strong performance [1] - Quarterly Performance: In Q4 2025, the company is expected to maintain a sequential revenue growth, sustaining over 20% growth for the year despite a high base in Q4 2024. The Non-IFRS net profit margin for Q4 2025 is projected to be stable at 35.1%, slightly lower than Q3 2025 [1] Industry: TIDES and CDMO Key Points - TIDES Business Growth: The TIDES business is expected to see revenue growth exceeding 90% in 2025. With large orders anticipated in 2026, the Chemistry business is also expected to maintain rapid growth and an upward trend in gross margins. The recovery of domestic demand and stable overseas demand are likely to enhance profit margins further [2] - Global Position in CDMO: WuXi AppTec has established itself as a leading player in the global small molecule CDMO sector. In 2025, the company supported the approval of 8 out of 30 new small molecule drugs by the FDA. Additionally, it has supported 11 out of 56 peptides and 12 out of 36 small molecules in the global GLP-1 drug category [2] - Potential Beneficiaries: The company is positioned to be a major beneficiary of future high-potential drugs such as oral GLP-1 and siRNA, which are expected to see significant market uptake [2]